OUTCOMES OF TACE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA LARGER THAN 10 CM

A ALI; K RIAZ

doi:10.54112/bcsrj.v2024i1.1435

Authors

A ALI Department of Radiology, Pakistan Kidney and Liver Institute (PKLI), Lahore, Pakistan
K RIAZ Department of Radiology, Pakistan Kidney and Liver Institute (PKLI), Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1435

Keywords:

Hepatocellular carcinoma, HCC, TACE, Transcatheter arterial chemoembolization

Abstract

Hepatocellular carcinoma (HCC) is a prevalent and aggressive liver malignancy, often presenting at advanced stages where surgical resection is not feasible. Transcatheter arterial chemoembolization (TACE) is a minimally invasive treatment modality that has shown promise in managing unresectable HCC, yet its effectiveness for large tumors (>10 cm) remains underexplored. Objective: To evaluate the outcomes of transcatheter arterial chemoembolization in patients with large unresectable hepatocellular carcinoma. Methods: A retrospective, case-control study was conducted in the Department of Interventional Radiology, PKLI, Lahore from September 2022 to September 2024. A total of 45 patients with hepatocellular carcinoma larger than 10 cm, eligible for TACE but refused aggressive treatment were selected as a control group of the study. A total of 50 age, tumor characteristics, and liver function-matched HCC patients who had undergone TACE were selected as the case group of the study. In the 2-3 months follow-up after TACE, tumor response by recorded by ultrasound or AFP assay. Results: The survival rate in cases (10 months, 95% CI: 5.1-14.3 months) was significantly higher than the control group (2 months, 95% CI: 1.05-3.22 months) (p<0.0001). The 1-year survival was 42% and 8% in cases and controls, respectively. The 2-year survival was 23% and 8%, respectively. Univariable analysis shows INR 1.2 or less, total bilirubin less than 1.6 mg/dL, liver reserve, and TACE were significantly associated with survival. Multi-variable analysis showed that INR of 1.2 or less and TACE remained significant for longer survival. Conclusion: TACE is a successful and safe treatment option for unresectable HCC tumors larger than 10 cm.

Downloads

Download data is not yet available.

References

Zhang Ch, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver International. 2022;42(9):2029-2041.

Reveron‐Thornton RF, Teng ML, Lee EY, Tran A, Vajanaphanich S, Tan EX, et al. Global and regional long‐term survival following resection for HCC in the recent decade: A meta‐analysis of 110 studies. Hepatology Communications. 2022;6(7):1813-1826.

Ghanaati H, Mohammadifard M, Mohammadifard M. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma. Journal of Family Medicine and Primary Care. 2021;10(10):3553-3560.

Liu J, Zhang J, Wang Y, Shu G, Lou C, Du Z. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Medicine. 2022;101(51):e32390.

Phan NH, Chun HJ, Oh JS, Kim SH, Choi BG. TACE vs. TARE for HCC≥ 8 cm: A propensity score analysis. Abdominal Radiology. 2024:1-11.

Chuang Y-H, Cheng Y-F, Tsang LL-C, Ou H-Y, Hsu H-W, Lim W-X, et al. Efficacy and safety of combined ethanol-lipiodol mixture and drug-eluting bead TACE for large HCC. Journal of Hepatocellular Carcinoma. 2023:81-90.

Chan KS, Tay WX, Cheo FY, Shelat VG. Preoperative transarterial chemoembolization (TACE)+ liver resection versus upfront liver resection for large hepatocellular carcinoma (≥ 5 cm): a systematic review and meta-analysis. Acta Chirurgica Belgica. 2023;123(6):601-617.

Li Q-J, He M-K, Chen H-W, Fang W-Q, Zhou Y-M, Xu L, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. Journal of Clinical Oncology. 2022;40(2):150-160.

Zhang X, El-Serag HB, Thrift AP. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes & Control. 2021;32:317-325.

Kong J, Li G, Chai J, Yu G, Liu Y, Liu J. Impact of postoperative complications on long-term survival after resection of hepatocellular carcinoma: a systematic review and meta-analysis. Annals of surgical oncology. 2021;28(13):8221-8233.

Aliyari Ghasabeh M, Shaghaghi M, Pandey A, Ameli S, Ambale Venkatesh B, Jacob A, et al. Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC). European radiology. 2021;31:1630-1641.

Zhou L, Zhang M, Chen S. Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis. Annals of Hepatology. 2023;28(2):100890.